Intranasal vasopressin like oxytocin increases social attention by influencing top-down control, but additionally enhances bottom-up control
- PMID: 34537624
- DOI: 10.1016/j.psyneuen.2021.105412
Intranasal vasopressin like oxytocin increases social attention by influencing top-down control, but additionally enhances bottom-up control
Abstract
The respective roles of the neuropeptides arginine vasopressin (AVP) and oxytocin (OXT) in modulating social cognition and for therapeutic intervention in autism spectrum disorder have not been fully established. In particular, while numerous studies have demonstrated effects of oxytocin in promoting social attention the role of AVP has not been examined. The present study employed a randomized, double-blind, placebo (PLC)-controlled between-subject design to explore the social- and emotion-specific effects of AVP on both bottom-up and top-down attention processing with a validated emotional anti-saccade eye-tracking paradigm in 80 healthy male subjects (PLC = 40, AVP = 40). Our findings showed that AVP increased the error rate for social (angry, fearful, happy, neutral and sad faces) but not non-social (oval shapes) stimuli during the anti-saccade condition and reduced error rates in the pro-saccade condition. Comparison of these findings with a previous study (sample size: PLC = 33, OXT = 33) using intranasal oxytocin revealed similar effects of the two peptides on anti-saccade errors, although with some difference in effects of specific face emotions, but a significantly greater effect of AVP on pro-saccades. Both peptides also produced a post-task anxiolytic effect by reducing state anxiety. Together these findings suggested that both AVP and OXT decrease goal-directed top-down attention control to social salient stimuli but that AVP more potently increased bottom-up social attentional processing.
Keywords: Anti-saccade task; Arginine vasopressin; Attention control; Emotion; Oxytocin.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Similar articles
-
Oxytocin reduces top-down control of attention by increasing bottom-up attention allocation to social but not non-social stimuli - A randomized controlled trial.Psychoneuroendocrinology. 2019 Oct;108:62-69. doi: 10.1016/j.psyneuen.2019.06.004. Epub 2019 Jun 15. Psychoneuroendocrinology. 2019. PMID: 31229634 Clinical Trial.
-
Oral Administration of Oxytocin, Like Intranasal Administration, Decreases Top-Down Social Attention.Int J Neuropsychopharmacol. 2022 Nov 17;25(11):912-923. doi: 10.1093/ijnp/pyac059. Int J Neuropsychopharmacol. 2022. PMID: 36053298 Free PMC article. Clinical Trial.
-
Oxytocin enhances attentional bias for neutral and positive expression faces in individuals with higher autistic traits.Psychoneuroendocrinology. 2015 Dec;62:352-8. doi: 10.1016/j.psyneuen.2015.09.002. Epub 2015 Sep 5. Psychoneuroendocrinology. 2015. PMID: 26372768
-
Central vasopressin and oxytocin release: regulation of complex social behaviours.Prog Brain Res. 2008;170:261-76. doi: 10.1016/S0079-6123(08)00422-6. Prog Brain Res. 2008. PMID: 18655888 Review.
-
Genes Related to Oxytocin and Arginine-Vasopressin Pathways: Associations with Autism Spectrum Disorders.Neurosci Bull. 2017 Apr;33(2):238-246. doi: 10.1007/s12264-017-0120-7. Epub 2017 Mar 10. Neurosci Bull. 2017. PMID: 28283809 Free PMC article. Review.
Cited by
-
Utility of Downstream Biomarkers to Assess and Optimize Intranasal Delivery of Oxytocin.Pharmaceutics. 2022 May 31;14(6):1178. doi: 10.3390/pharmaceutics14061178. Pharmaceutics. 2022. PMID: 35745751 Free PMC article.
-
Oxytocin, but not vasopressin, decreases willingness to harm others by promoting moral emotions of guilt and shame.Mol Psychiatry. 2024 Nov;29(11):3475-3482. doi: 10.1038/s41380-024-02590-w. Epub 2024 May 20. Mol Psychiatry. 2024. PMID: 38769372 Free PMC article. Clinical Trial.
-
Neural and behavioral evidence for oxytocin's facilitatory effects on learning in volatile and stable environments.Commun Biol. 2024 Jan 19;7(1):109. doi: 10.1038/s42003-024-05792-8. Commun Biol. 2024. PMID: 38242969 Free PMC article.
-
Effects of arginine vasopressin on human anxiety and associations with sex, dose, and V1a-receptor genotype.Psychopharmacology (Berl). 2024 Jun;241(6):1177-1190. doi: 10.1007/s00213-024-06551-7. Epub 2024 Feb 15. Psychopharmacology (Berl). 2024. PMID: 38358527 Clinical Trial.
-
Vasopressin as Possible Treatment Option in Autism Spectrum Disorder.Biomedicines. 2023 Sep 22;11(10):2603. doi: 10.3390/biomedicines11102603. Biomedicines. 2023. PMID: 37892977 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
